Literature DB >> 9561949

Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia.

P F Buckley1.   

Abstract

Comorbid substance abuse (SA) in schizophrenia is a significant problem. Moreover, these patients are particularly difficult to treat. This report reviews the pharmacological management of comorbid SA and schizophrenia and a case report is provided to illustrate the potential of novel antipsychotic medications.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9561949     DOI： 10.1016/s0740-5472(97)00134-7

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN： 0740-5472


  5 in total

Review 1.  Pharmacological treatment of schizophrenia and co-occurring substance use disorders.

Authors:  David A Smelson; Lisa Dixon; Thomas Craig; Stephen Remolina; Steven L Batki; Noosha Niv; Richard Owen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 2.  Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.

Authors:  Douglas M Ziedonis; David Smelson; Richard N Rosenthal; Steven L Batki; Alan I Green; Renata J Henry; Ivan Montoya; Joseph Parks; Roger D Weiss
Journal:  J Psychiatr Pract       Date:  2005-09       Impact factor: 1.325

3.  Management of "dual diagnosis" patients : consensus, controversies and considerations.

Authors:  D Basu; N Gupta
Journal:  Indian J Psychiatry       Date:  2000-01       Impact factor: 1.759

4.  Potential benefits of quetiapine in the treatment of substance dependence disorders.

Authors:  S Pirzada Sattar; Subhash C Bhatia; Frederick Petty
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

5.  Olanzapine improves deficient sensory inhibition in DBA/2 mice.

Authors:  Johanna K Simosky; Robert Freedman; Karen E Stevens
Journal:  Brain Res       Date:  2008-07-25       Impact factor: 3.252
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.